Safety of 8-Aminoquinoline
antimalarial medicines [Internet].
Tafenoquine is an investigational 8-aminoquinoline
derivative with activity against the P.
CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline
, anti-malarial drug primaquine.
The endoperoxide OZ439, currently in Phase II clinical trials, and a new 8-aminoquinoline
, NPC-1161B, also demonstrated transmission-blocking potential.
A new 8-aminoquinoline
tafenoquine is on clinical trial as a potential replacement for primaquine to treat Plasmodium vivax malaria (Shanks 2001) and holds promise as a prophylactic against Plasmodium falciparum (Shanks 2001).
In addition, tafenoquine is a long-acting 8-aminoquinoline
now in clinical trials to replace 2 weeks of primaquine for nonfalciparum malaria.
Primaquine, an 8-aminoquinoline
was covalently coupled onto oxidized gum arabic via imine bond and simultaneously fabricated into microspheres of less than 2 [micro]m in size by heat denaturation in a reverse emulsion of 1:1 light paraffin oil and toluene stabilized by sorbitan sesquioleate as the surfactant.
These include an 8-aminoquinoline
derivative under pre-clinical evaluation for the treatment of malaria, leishmania and pneumocystis pneumonia.
Bhat BK, Seth M, Bhaduri AP (1984) Recent developments in 8-aminoquinoline
Mass administration of an antimalarial drug combining 4-aminoquinoline and 8-aminoquinoline
Structural features of Plasmodium cytochrome b that may underlie susceptibility to 8-aminoquinolines